2-[(3α,7α,12α-trihydroxy-24-oxo-5β-cholan-24-yl)amino]ethanesulfinic acid | 1562403-24-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 2-[(3α,7α,12α-trihydroxy-24-oxo-5β-cholan-24-yl)amino]ethanesulfinic acid
• 英文别名: 2-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfinic acid
• CAS: 1562403-24-0
• 化学式: C₂₆H₄₅NO₆S
• 分子量: 499.712
• InChiKey: SWQBSNWVJNBZOJ-HZAMXZRMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  146
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• Reducing Risk of Contracting Clostridium-Difficile Associated Disease
  申请人：The Regents of the Nevada System of Higher Education on behalf of the University of Neveda

  公开号：US20140045808A1

  公开（公告）日：2014-02-13

  A method of treating a patient to reduce risk of developing Clostridium difficile -associated disease or reducing existing Clostridium difficile -associated disease in a mammalian subject involves administering to a mammalian subject an effective amount of a germination-inhibiting compound derived from taurocholate. Novel compounds of this class are also provided.

  治疗患者以减少发生梭菌类难辨梭菌相关疾病的风险或减少哺乳动物主体中已存在的梭菌类难辨梭菌相关疾病的方法涉及向哺乳动物主体投入源自牛磺胆酸的抑制萌发化合物的有效量。此类新颖化合物也提供。
• GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY
  申请人：Indiana University Research and Technology Corporation

  公开号：EP2569000B1

  公开（公告）日：2017-09-27
• US9079935B2
  申请人：——

  公开号：US9079935B2

  公开（公告）日：2015-07-14
• US9862744B2
  申请人：——

  公开号：US9862744B2

  公开（公告）日：2018-01-09
• [EN] FGF21 C-TERMINAL PEPTIDE OPTIMIZATION<br/>[FR] OPTIMISATION PEPTIDIQUE À FGF21 C-TERMINAL
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2017180988A2

  公开（公告）日：2017-10-19

  Disclosed herein are modified C-terminal fragments of FGF21 optimized for binding to Klotho β or antagonizing FGF21 activity. FGF21 peptides modified to comprise modifications to the C-terminal amino acid sequence are disclosed that have enhanced activity at the FGF21 receptor. Additionally, conjugates formed between the optimized FGF21 peptide fragments and insulin like peptides or nuclear hormone receptor ligands are provided.